Table 3.

Univariate and Multivariate Cox Regression Analyses for PFS and OS in Isolated RPLNs

	UVA PFS	MVA PFS	UVA OS	MVA OS
	HR 95% CI P	HR 95% CI P	HR 95% CI P	HR 95% CI P
Age, year (≥50 vs.<50)	1.63 0.44–5.99 0.47	NI	0.71 0.11–4.42 0.71	NI
Sex (male vs female)	1.57 0.52–4.72 0.42	NI	3.21 0.57–17.9 0.19	NI
Primary site (colon vs rectum)	0.57 0.15–2.11 0.39	NI	0.37 0.04–3.25 0.37	NI
Tumor grade (G3 vs G2)	0.29 0.07–1.23 0.09	0.38 0.08–1.79 0.16	0.24 0.04–1.46 0.12	0.10 0.01–1.11 0.06
T-category (≤T3 vs >T4)	1.79 0.61–5.33 0.29	NI	1.09 0.25–4.77 0.91	NI
N-category (N2 vs N0–1)	0.19 0.05–0.71 0.01	0.18 0.04–0.79 0.02	0.11 0.01–1.07 0.05	0.14 0.01–1.31 0.08
RAS and BRAF status (wild type vs mutant type)	0.61 0.10–3.74 0.59	NI	1.27 0.07–21.8 0.87	NI
Interval, months (>12 vs≤12)	0.24 0.06–0.89 0.03	0.14 0.02–0.88 0.04	0.27 0.05–1.57 0.15	0.31 0.07–1.68 0.31
LN site (suprarenal vs infrarenal)	1.09 0.36–3.27 0.88	NI	3.98 0.46–34.4 0.21	NI
LN size (≤2cm vs >2cm)	4.87 1.15–20.6 0.03	9.04 0.97–83.5 0.05	0.52 0.05–5.08 0.57	NI
Radiation dose (<50 Gy vs≥50 Gy)	0.31 0.07–1.28 0.10	0.08 0.01–1.26 0.11	0.33 0.06–1.88 0.21	NI
RECIST (CR+PR vs SD+PD)	5.05 1.55–16.5 0.01	5.81 1.17–29.0 0.03	13.1 1.46–118 0.02	22.0 1.58–308 0.02
Targeted therapy (Yes vs No)	0.86 0.26–2.86 0.81	NI	2.45 0.29–21.1 0.41	NI
Targeted drug (cet vs bev)	0.74 0.07–8.41 0.81	NI	0.01 0–500 0.58	NI

Abbreviations: bev, bevacizumab; CI, confidence interval; CR, complete response; cet, cetuximab; HR, hazard ratio; LN, lymph node; MVA, multivariate analyses; mutant type, RAS-BRAF mutant; N, lymph node; NI, not included; OS, overall survival; PFS, progression-free survival; PR, partial response; PD, progressive disease; RPLN, retroperitoneal lymph node; RECIST, Response Evaluation Criteria in Solid Tumor; SD, stable disease; T, tumor; UVA, univariate analyses; wild type, RAS wild type.